Alto Neuroscience completes enrollment in Phase 2 trial for first-of-its-kind schizophrenia cognitive treatment

Alto met its enrollment goal with 83 patients across 13 US clinical sites

FDA grants priority review to Bristol Myers Squibb's Iberdomide for multiple myeloma

Iberdomide has the potential to be the first approved CELMoD agent

Biofrontera scores FDA filing acceptance for Ameluz PDT in skin cancer breakthrough

If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US

STADA & Bio-Thera bag European nod for Gotenfia

Clinigen bags Japan's nod to human milk-based medicine for preterm infants

PreemieFort Enteral Solution's approval marks the first time a nutritional product derived from human milk has been recognized as a prescription medicine anywhere in the world

Lundbeck’s bocunebart shows breakthrough potential in migraine prevention

Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide

BridgeBio reports breakthrough results in Phase 3 achondroplasia trial

Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone

Centivax launches first human trial of universal flu vaccine

Akums surges in Q3 FY26 with 15% revenue jump, bags key EU & UK nods

Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore

FDA nod to Acrotech's new eczema treatment

ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis